



**BROWN**  
Alpert Medical School

# Poster Summary Slides

1103722

**Androgen Deprivation Therapy in Prostate Cancer:  
Assessing the Educational Need Among Urologists**

---



## Androgen Deprivation Therapy in Prostate Cancer: Assessing the Educational Need Among Urologists

*Pamela Ellsworth, Providence, RI; Gina Carithers, Berkeley, CA; Rachel DiPaolo and Purvi Kobawala Smith, Ramsey, NJ*

### **Goal**

- Assess the level of comfort in prescribing ADT and the patterns of ADT use; identify educational needs amongst urologists with regard to ADT.

### **Method**

- A 7-question survey was electronically distributed to UroToday® subscribers during the period of October 8–20, 2010. Responses were received from 345 participants, although not all of them were completed.

### **Key Findings**


- Considerable variability in the monitoring of testosterone levels in patients on ADT.
- Lack of confidence with regard to identifying men who might benefit from ADT, the optimal timing of ADT, the use of intermittent versus continuous ADT, and mitigating side effects.
- These findings support the need for further education related to the management of advanced prostate cancer with ADT.

ADT=Androgen Deprivation Therapy

1103722

## Androgen Deprivation Therapy in Prostate Cancer: Assessing the Educational Need Among Urologists

How often do you monitor testosterone levels in men undergoing ADT? (n=331)



### Results

- Almost 50% of prostate cancer patients were being treated with ADT
- 35% check testosterone levels 1x/yr; 34% check levels 2-4x/yr; 23% never check testosterone levels in men on ADT
- Most common barriers to ADT treatment were AEs and reimbursement- and/or cost-related issues

### Confidence Levels in Clinical Scenarios Related to Use of ADT

